71 completed, 13 unknown, 8 terminated, 3 recruiting. 50 Phase 4, 21 Phase 3, 14 Not applicable, 9 Phase 2, 3 Phase 1.
Follow Nebivolol: new trials by email Literature Review of Nebivolol trials Research Report on Nebivolol
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Impact of Medically Supervised Performance-Enhancing Substances (PES) on Elite Athletes Testosterone Enanthate, Testosterone Cypionate, Testosterone Propionate - Safety and Impact of Medically Supervised Performance Enhancing Substance Usage in Healthy Elite Athletes | Not applicable | Enrolling by invitation | Enhanced Emirates Limited | 60 | 2026-03-12 | 2026-05-06 |
| Evaluation of the Cardioprotective Effect of Nebivolol on Trastuzumab-Induced Cardiotoxicity in Breast Cancer Patients Nebivolol 5 mg - HER2-positive Breast Cancer | Phase 2 | Recruiting | Ain Shams University | 56 | 2025-01-01 | 2025-11-19 |
| Beta-blockade in Unruptured Intracranial Aneurysm Nebivolol, Placebo - Intracranial Aneurysm | Phase 4 | Not yet recruiting | Jagiellonian University | 100 | 2025-01-01 | 2024-02-08 |
| Efficacy of Targeted Medical Therapy in Angina and Nonobstructive Coronary Arteries Amlodipine, Nebivolol, Placebo - Angina Pectoris, Microvascular Angina | Phase 2 / Phase 3 | Recruiting | Stanford University | 150 | 2024-10-10 | 2024-11-27 |
| Determination of Drug Levels for Pharmacotherapy of Heart Failure Nebivolol, Valsartan and Sacubitril, Carvedilol - Cardiovascular Diseases, Heart Failure With Reduced Ejection Fraction | Phase 4 | Unknown | University Hospital Ostrava | 100 | 2024-03-01 | 2024-01-18 |
| Clinical Application of Simcyp-Guided Doses of Antihypertensive Drugs in Cirrhotic Patients Nebivolol 5 mg, Carvedilol 12.5 mg, Nebivolol 2.5 mg - Liver Cirrhosis, Arterial Hypertension | Phase 4 | Completed | Kafrelsheikh University | 40 | 2024-03-01 | 2026-02-09 |
| Open-label inteRventional Clinical Trial to Assess Efficacy and Safety of the exteMporaneous combInation of Nebivolol and Ramipril in hypertenSIve pAtients Nebivolol 5 mg, Ramipril 2.5/5/10 mg - Hypertension | Phase 4 | Completed | Menarini International Operations Luxembourg SA | 266 | 2023-10-02 | 2025-04-24 |
| Effectiveness and Safety of Combination of Nebivolol and Amlodipine in Hypertensive Patients Versus Each Monotherapy Nebivolol, Amlodipine - Hypertension | Phase 4 | Completed | Menarini International Operations Luxembourg SA | 301 | 2022-05-12 | 2025-02-04 |
| Evaluating the Outcome of Cardio Selective beta1- Blockers Use in Patients With Copd Nebivolol Tablets - Copd | Phase 4 | Unknown | Ain Shams University | 30 | 2021-10-01 | 2021-04-14 |
| To Evaluate Drug-drug Interactions Between DWN12088 and Nebivolol or Paroxetine in Healthy Volunteers DWN12088, Nebivolol, Paroxetine - Idiopathic Pulmonary Fibrosis | Phase 1 | Completed | Daewoong Pharmaceutical Co. LTD. | 24 | 2021-06-30 | 2021-08-04 |
| Effectiveness and Safety of Combination of Nebivolol and Zofenopril in Hypertensive patIents Versus Each Monotherapy Zofenopril 30 mg, Nebivolol 5 mg, Zofenopril 30 mg + Nebivolol 5 mg - Hypertension | Phase 4 | Completed | Menarini International Operations Luxembourg SA | 283 | 2021-05-26 | 2024-09-20 |
| Impact of Beta-blockers on Physical Function in HFpEF Beta blockers - Heart Failure, Heart Failure, Diastolic | Phase 4 | Completed | Weill Medical College of Cornell University | 9 | 2021-04-01 | 2023-09-08 |
| Pilot Deprescribing N-of-1 Trials for Beta-blockers in HFpEF Beta blockers - Heart Failure, Heart Failure, Diastolic | Phase 4 | Completed | Weill Medical College of Cornell University | 9 | 2021-04-01 | 2024-04-09 |
| Managing Endothelial Dysfunction in COVID-19 : A Randomized Controlled Trial at LAUMC Atorvastatin + L-arginine + Folic acid + Nicorandil + Nebivolol, Placebo - Covid19 | Phase 3 | Unknown | Lebanese American University Medical Center | 42 | 2021-01-10 | 2022-02-14 |
| Rate Control in Patients With Atrial Fibrillation Atenolol, Bisoprolol, Metoprolol, Nebivolol, Propranolol, Diltiazem, Verapamil, digoxin - Atrial Fibrillation, Rate Control | Not applicable | Completed | National Taiwan University Hospital | 13 | 2020-10-21 | 2026-01-16 |
| Efficacy of Medical Therapy in Women and Men With Angina and Myocardial Bridging Nebivolol, Diltiazem, Placebo - Myocardial Bridging | Phase 2 | Terminated | Stanford University | 5 | 2020-10-15 | 2025-02-25 |
| Dapagliflozin on Hypotensive Heart Failure Patients After Sacubitril/Valsartan Therapy Dapagliflozin, Sacubitril-Valsartan, Beta blocker - Hypotension, Heart Failure | Phase 4 | Completed | Cheng-Hsin General Hospital | 78 | 2020-05-29 | 2021-08-02 |
| Nutraceuticals and Drug Treatment in Frail Older Adults Nutraceuticals - Frailty | Unknown | University of Campania Luigi Vanvitelli | 485 | 2020-04-01 | 2022-05-10 | |
| ACEI or ARB and COVID-19 Severity and Mortality in US Veterans ACEI/ARB, Non-ACEI/ARB, ACEI - Hypertension, COVID | Completed | University of Utah | 22213 | 2020-01-19 | 2021-04-28 | |
| Effect of Different Antihypertensive Drugs on Central Blood Pressure Nebivolol - Hypertension | Not applicable | Unknown | Korea University Anam Hospital | 110 | 2019-01-06 | 2022-04-14 |
Showing 20 of 101. Sign in to see all of them.
Hypertension (64) · Heart Failure (9) · Heart Diseases (3) · Heart Failure, Diastolic (3) · Motor Activity (3) · Prehypertension (3) · Angina Pectoris (2) · Breast Neoplasms (2) · Cardiovascular Diseases (2) · Coronary Artery Disease (2) · Diabetes Mellitus (2) · Diabetes Mellitus, Type 2 (2) · Hypoxia (2) · Microvascular Angina (2) · Multiple System Atrophy (2)
Forest Laboratories (14) · Mylan Bertek Pharmaceuticals (9) · Emory University (3) · Menarini International Operations Luxembourg SA (3) · Vanderbilt University (3) · Weill Medical College of Cornell University (3) · Ain Shams University (2) · Aristotle University Of Thessaloniki (2) · Korea University Anam Hospital (2) · Mayo Clinic (2) · Stanford University (2) · University of California, San Diego (2) · University of Chicago (2) · University of Colorado, Boulder (2) · University of Florida (2)
United States (64) · Italy (6) · South Korea (5) · Egypt (3) · Puerto Rico (3) · United Kingdom (3) · Denmark (2) · Greece (2) · Poland (2) · Taiwan (2) · Austria (1) · Belgium (1) · Bulgaria (1) · Czechia (1) · Estonia (1)
Betty S. Riggs, MD, MBA (7) · David B Bharucha, MD, PhD, FACC (2) · Italo Biaggioni, MD (2) · John Shea, MS (2) · Manfred Stapff, MD, PhD (2) · Parag Goyal, MD (2) · Tatjana Lukic, MD., M.Sc. (2) · Wanpen Vongpatanasin, MD (2) · Adam P Bress, PharmD, MS (1) · Ahmed A Ali, PhD (1) · Alfonso Santos, MD (1) · Anna Meta D Kristensen, MD (1) · Arshed Quyyumi, MD (1) · Benjamin Epstein, PharmD (1) · Betty S Riggs, MD, MBA (1)
PMID 10109801, PMID 10851208, PMID 11927799, PMID 12119802, PMID 12923400, PMID 15738343, PMID 16391172, PMID 16533484, PMID 16601194, PMID 17188619, PMID 17911499, PMID 18426998, PMID 19047577, PMID 19430350, PMID 19738158, PMID 21297499, PMID 21450573, PMID 21536983, PMID 21827541, PMID 22353614, PMID 22708640, PMID 22801444, PMID 23266540, PMID 23327629, PMID 23332366, PMID 23519546, PMID 23547240, PMID 24881993, PMID 25193873, PMID 25492835, PMID 25681236, PMID 26116459, PMID 26285691, PMID 26811165, PMID 26876066, PMID 27098105, PMID 27113048, PMID 27199121, PMID 27809882, PMID 29122812, PMID 29184167, PMID 29581554, PMID 30153111, PMID 31687205, PMID 32395337, PMID 32446298, PMID 33891615, PMID 34474011, PMID 34969173, PMID 35287171
2018 (1), K23GM112014 (1), K76AG064428 (1)